# Who are Amgen's customers? Who does Amgen earn revenue from?
Canonical: https://valuechain.wiki/amgen · Facet: customers · Updated: 2026-09-04T23:12:09.296557+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Amgen's confirmed revenue counterparties include 카디널 헬스, 맥케슨, 센코라 plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 4 revenue edges, backed by 4 dated sources, 1 of them primary filings (as of 2026-09-04).

### 카디널 헬스 (high)  → /cardinal-health.md
- note: No.3 wholesaler. 16% of total gross revenues in FY2025 ($12.56B gross product sales). The three wholesalers combined were 77%.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for 2025, 2024 and 2023. On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenues."

### 맥케슨 (high)  → /mckesson.md
- note: Largest U.S. drug wholesaler. Accounted for 34% of Amgen's total gross revenues in FY2025 ($26.25B gross product sales), the single biggest channel.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for 2025, 2024 and 2023. On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenues."

### 센코라 (high)  → /cencora.md
- note: No.2 wholesaler (formerly AmerisourceBergen). 27% of total gross revenues in FY2025 ($20.99B gross product sales).
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for 2025, 2024 and 2023. On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenues."

### 비만·골질환 시장 (마리타이드 개발) (mid)
- note: MariTide, a once-monthly antibody-peptide conjugate (GLP-1 agonist plus GIPR antagonist), is in six global Phase 3 studies — two started March 2025, four more November 2025. Primary readouts early 2027. A third contender challenging the Lilly and Novo GLP-1 duopoly.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "In March 2025, we announced the initiation of two global Phase 3 studies to evaluate MariTide, a differentiated antibody-peptide conjugate that activates the GLP-1 receptor and antagonizes the GIPR, in chronic weight management; in November 2025 we announced four additional global Phase 3 studies were underway."
- [mentions] TIKR (EN, analysis, published 2026-02-01) https://www.tikr.com/blog/abbvie-posts-record-61b-revenue-as-skyrizi-and-rinvoq-surge-past-peak-humira-sales: "MariTide Phase III readouts in early 2027."
- [confirms] TheBioNews (KO, news, published 2025-03-12) https://www.thebionews.net/news/articleView.html?idxno=13284: "Amgen began two Phase 3 trials of once-monthly obesity candidate MariTide, with key data expected early 2027."
- [confirms] FierceBiotech (EN, news, published 2025-03-11) https://www.fiercebiotech.com/biotech/amgen-enters-maritime-launching-2-late-stage-obesity-trials-maritide: "Amgen launched two late-stage (Phase 3) obesity trials for MariTide; Phase 2 showed up to ~20% weight loss at 52 weeks."

Reverse side: https://valuechain.wiki/amgen/suppliers.md · Ripple: https://valuechain.wiki/amgen/ripple.md

---
Full node: https://valuechain.wiki/amgen.md · JSON: https://valuechain.wiki/amgen.json